Stem Cell Infusion ( DrugBank: - )

---

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
28	全身性アミロイドーシス	3
60	再生不良性貧血	3
65	原発性免疫不全症候群	4
284	ダイアモンド・ブラックファン貧血	2
285	ファンコニ貧血	1

28. 全身性アミロイドーシス

---

臨床試験数 : 261 /  薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02489500 (ClinicalTrials.gov)	June 2015	9/3/2015	Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib	Phase III Trial of High-dose Melphalan and Stem Cell Transplantation Versus High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis	AL Amyloidosis	Drug: Bortezomib;Drug: Melphalan;Drug: Neupogen;Procedure: Stem Cell Collection;Procedure: Stem cell infusion	Boston Medical Center	NULL	Terminated	18 Years	N/A	All	3	Phase 3	United States
2	NCT00790647 (ClinicalTrials.gov)	June 2008	12/11/2008	Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis	Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis	Multiple Myeloma	Biological: filgrastim;Drug: bortezomib;Drug: melphalan;Procedure: Stem Cell Infusion	Boston Medical Center	NULL	Completed	18 Years	65 Years	All	10	Phase 2	United States
3	NCT00075608 (ClinicalTrials.gov)	August 2001	9/1/2004	2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis	Phase II Trial of Second Autologous Transplantation in AL Amyloidosis	Multiple Myeloma;Plasma Cell Neoplasm	Biological: filgrastim;Drug: melphalan;Procedure: autologous stem cell transplantation;Procedure: stem cell infusion	Boston Medical Center	NULL	Terminated	18 Years	65 Years	All	12	Phase 2	United States

60. 再生不良性貧血

---

臨床試験数 : 235 /  薬物数 : 381 - (DrugBank : 83) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 160

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100047288	2021-06-01	2021-06-11	Efficacy and safety of combined immunosuppressive therapy plus umbilical cord blood infusion in myelodysplastic syndromes/aplastic anemia patients: a clinical observation study	Efficacy and safety of combined immunosuppressive therapy plus umbilical cord blood infusion in myelodysplastic syndromes/aplastic anemia patients: a clinical observation study	myelodysplastic syndromes/aplastic anemi	Experimental group1:According to the classification, ATG + CsA/CSA alone is used as the pretreatment plan/supportive treatment + non-blood cord blood stem cell infusion treatment;Experimental group2:Decitabine+cytarabine/decitabine alone is used as the pretreatment plan/supportive treatment+non-blood cord blood stem cell infusion treatment according to the classification;	The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)	NULL	Recruiting	18	90	Both	Experimental group1:10;Experimental group2:10;		China
2	NCT00578903 (ClinicalTrials.gov)	February 2002	19/12/2007	Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia	Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors (SAA MUD)	Aplastic Anemia	Drug: Cytoxan;Drug: Campath;Radiation: Total Body Irradiation (TBI);Drug: FK-506;Drug: Methotrexate;Procedure: Stem cell infusion	Baylor College of Medicine	The Methodist Hospital System;Texas Children's Hospital;Center for Cell and Gene Therapy, Baylor College of Medicine	Terminated	N/A	60 Years	All	22	Phase 2	United States
3	NCT00590460 (ClinicalTrials.gov)	July 2001	26/12/2007	Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia	Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia	Fanconi Anemia;Severe Aplastic Anemia	Biological: CAMPATH-1H;Biological: Anti-CD45;Drug: Fludarabine;Procedure: Stem cell infusion	Baylor College of Medicine	The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine	Terminated	N/A	N/A	All	5	Phase 1/Phase 2	United States

65. 原発性免疫不全症候群

---

臨床試験数 : 482 /  薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01856582 (ClinicalTrials.gov)	October 2010	15/5/2013	CD34+ Stem Cell Infusion to Augment Graft Function	Post Transplant CD34+ Selected Stem Cell Infusion to Augment Graft Function in Children With Primary Immunodeficiency Diseases and Bone Marrow Failure Syndromes	Waning Donor Chimerism;Waning Immune Function;Primary Immunodeficiency Disease(s);Bone Marrow Failure	Biological: CD34+	Children's Hospital Medical Center, Cincinnati	Hoxworth Blood Center	Terminated	N/A	35 Years	All	23	Phase 2	United States
2	NCT00579137 (ClinicalTrials.gov)	October 2007	19/12/2007	Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders	CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders	Severe Combined Immunodeficiency Disease;Severe Primary Immunodeficiency Disorder;Undefined T Cell Deficiency Disorder;Wiskott-Aldrick Syndrome	Biological: Campath -1H;Drug: Fludarabine;Biological: Anti-CD45;Procedure: Stem cell infusion	Baylor College of Medicine	Center for Cell and Gene Therapy, Baylor College of Medicine;Texas Children's Hospital	Terminated	N/A	N/A	All	3	Phase 1/Phase 2	United States
3	NCT00578643 (ClinicalTrials.gov)	March 2004	19/12/2007	Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease	HLA Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease	Chronic Granulomatous Disease	Drug: Busulfan;Biological: Alemtuzumab;Drug: Cyclophosphamide;Drug: Fludarabine;Drug: Cyclosporine;Procedure: Stem Cell Infusion	Baylor College of Medicine	NULL	Completed	N/A	N/A	All	15	Phase 2	United States
4	NCT00176852 (ClinicalTrials.gov)	June 2002	12/9/2005	Stem Cell Transplant for Hemoglobinopathy	Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism	Sickle Cell Disease;Thalassemia;Severe Congenital Neutropenia;Diamond-Blackfan Anemia;Shwachman-Diamond Syndrome	Drug: Busulfan, Fludarabine, ATG, TLI;Drug: Busulfan, Cyclophosphamide, ATG, GCSF;Drug: Campath, Fludarabine, Cyclophosphamide;Radiation: Total Body Irradiation;Procedure: Stem cell infusion	Masonic Cancer Center, University of Minnesota	National Marrow Donor Program	Completed	N/A	50 Years	All	22	Phase 2/Phase 3	United States

284. ダイアモンド・ブラックファン貧血

---

臨床試験数 : 37 /  薬物数 : 110 - (DrugBank : 34) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01419704 (ClinicalTrials.gov)	May 2011	16/8/2011	Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies	Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies	Anemia, Sickle Cell;Complex and Transfusion-dependent Hemoglobinopathies;Thalassemia;Diamond-Blackfan Anemia;Bone Marrow Failure Syndromes;Alpha-Thalassemia;Beta-Thalassemia	Biological: Enriched Hematopoetic Stem Cell Infusion	Talaris Therapeutics Inc.	Duke University	Suspended	N/A	45 Years	All	30	Phase 1/Phase 2	United States
2	NCT00176852 (ClinicalTrials.gov)	June 2002	12/9/2005	Stem Cell Transplant for Hemoglobinopathy	Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism	Sickle Cell Disease;Thalassemia;Severe Congenital Neutropenia;Diamond-Blackfan Anemia;Shwachman-Diamond Syndrome	Drug: Busulfan, Fludarabine, ATG, TLI;Drug: Busulfan, Cyclophosphamide, ATG, GCSF;Drug: Campath, Fludarabine, Cyclophosphamide;Radiation: Total Body Irradiation;Procedure: Stem cell infusion	Masonic Cancer Center, University of Minnesota	National Marrow Donor Program	Completed	N/A	50 Years	All	22	Phase 2/Phase 3	United States

285. ファンコニ貧血

---

臨床試験数 : 59 /  薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 155

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00590460 (ClinicalTrials.gov)	July 2001	26/12/2007	Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia	Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia	Fanconi Anemia;Severe Aplastic Anemia	Biological: CAMPATH-1H;Biological: Anti-CD45;Drug: Fludarabine;Procedure: Stem cell infusion	Baylor College of Medicine	The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine	Terminated	N/A	N/A	All	5	Phase 1/Phase 2	United States

先頭へ